Keywords: USA, Pay-to-delay, GPhA, FTC, Patent settlements

US generic group GPhA slams FTC position on patent settlements as “misguided”

Article | 29 July 2010

Commenting on US Federal Trade Commission Chairman Jon Leibowitz’ testimony before the House of Representatives Committee on the Judiciary, Subcommittee on Courts and Competition Policy (The Pharma Letter July 28), the Generic Pharmaceutical Association (GPhA) described it as misguided and failing to present the whole story regarding patent settlements.

The six months of data presented by the FTC does not override the fact that over the past 10 years patent settlements – often described as “pay-to-delay” deals - have enabled dozens of first-time generics to come to market many months before patents on the counterpart brand drugs expired. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in